Indication
Hereditary orotic aciduria, type I
Hereditary orotic aciduria, type I is an extremely rare autosomal recessive inborn error of pyrimidine metabolism caused by pathogenic variants in the UMPS gene. Read more about Hereditary orotic aciduria, type I
2 drugs 2 manufacturers
Drugs that treat it
Common Hereditary orotic aciduria, type I therapies.
XURIDEN (uridine triacetate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHereditary orotic aciduria, type I is an extremely rare autosomal recessive inborn error of pyrimidine metabolism caused by pathogenic variants in the UMPS gene.
This genetic defect results in a combined deficiency of both functional enzymatic domains of uridine monophosphate synthase: orotate phosphoribosyltransferase and orotidine-5'-monophosphate decarboxylase.
Pathophysiologically, the inability to synthesize uridine monophosphate impairs normal DNA and RNA synthesis and triggers massive urinary excretion of orotic acid.
Typically presenting in infancy, defining clinical manifestations include severe refractory megaloblastic anemia unresponsive to vitamin B12 and folate, failure to thrive, developmental delays, and orotic acid crystalluria, which may lead to urinary tract obstruction.
- rarediseases.org
Hereditary orotic aciduria, type I is an extremely rare autosomal recessive inborn error of pyrimidine metabolism caused by pathogenic variants in the UMPS gene This genetic defect results in a combined deficiency of both functional enzymatic domains of uridine monophosphate synthase: orotate phosphoribosyltransferase and orotidine-5'-monophosphate decarboxylase Typically presenting in infancy, defining clinical manifestations include severe refractory megaloblastic anemia unresponsive to vitami...
- nih.gov
Hereditary orotic aciduria, type I is an extremely rare autosomal recessive inborn error of pyrimidine metabolism caused by pathogenic variants in the UMPS gene This genetic defect results in a combined deficiency of both functional enzymatic domains of uridine monophosphate synthase: orotate phosphoribosyltransferase and orotidine-5'-monophosphate decarboxylase
- patientworthy.com
Pathophysiologically, the inability to synthesize uridine monophosphate impairs normal DNA and RNA synthesis and triggers massive urinary excretion of orotic acid
- orpha.net
Pathophysiologically, the inability to synthesize uridine monophosphate impairs normal DNA and RNA synthesis and triggers massive urinary excretion of orotic acid Typically presenting in infancy, defining clinical manifestations include severe refractory megaloblastic anemia unresponsive to vitamin B12 and folate, failure to thrive, developmental delays, and orotic acid crystalluria, which may lead to urinary tract obstruction
- pharmacytimes.com
Typically presenting in infancy, defining clinical manifestations include severe refractory megaloblastic anemia unresponsive to vitamin B12 and folate, failure to thrive, developmental delays, and orotic acid crystalluria, which may lead to urinary tract obstruction
Personalize your experience
Follow Hereditary orotic aciduria, type I and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.